Can I Take Melatonin with Low-Dose Naltrexone?
At a glance
- Naltrexone / generic name; standard-dose brand products (ReVia, Vivitrol) are FDA-approved at 50 mg (oral) or as a monthly injection for opioid or alcohol use disorder
- Low-dose naltrexone (LDN) / 1.5 mg to 4.5 mg, compounded; this dose and use is off-label and not FDA-approved for any indication
- Melatonin / an over-the-counter dietary supplement in the United States, not FDA-regulated as a drug; typical sleep dose 0.5 mg to 5 mg
- Interaction type / no known pharmacokinetic interaction; a plausible but unproven pharmacodynamic overlap on inflammatory and glucose pathways
- Practical timing question / whether to separate bedtime dosing, addressed below
- Off-label LDN uses discussed in the literature / fibromyalgia, Crohn disease, multiple sclerosis-related symptoms, other autoimmune conditions
Naltrexone is an opioid receptor antagonist. At the standard 50 mg dose it is FDA-approved to help prevent relapse in opioid or alcohol use disorder. At the 1.5 mg to 4.5 mg range used in "low-dose naltrexone" protocols, it is a compounded, off-label preparation studied mainly in small trials for pain and autoimmune conditions. Melatonin is a pineal hormone sold in the US as an unregulated dietary supplement, most often used for sleep-onset difficulty and jet lag. These are pharmacologically distinct molecules with different receptor targets, and confusing LDN with standard-dose naltrexone, or confusing supplement-grade melatonin with a regulated sleep medication, is a common source of error worth clearing up before discussing interactions.
The direct answer
No pharmacokinetic interaction between naltrexone and melatonin has been reported in the literature reviewed for this article, and the two compounds are metabolized through separate pathways: naltrexone is converted mainly by carbonyl reductase to 6-beta-naltrexol, while melatonin is metabolized largely by hepatic CYP1A2. This means neither drug is expected to raise or lower blood levels of the other. What remains unproven is whether the two agents' overlapping, but mechanistically distinct, effects on inflammatory signaling and on endogenous opioid tone produce any clinically meaningful additive effect in humans, because no controlled trial has tested the combination directly. Anyone with diabetes, pre-diabetes, or a medication that inhibits CYP1A2 should treat melatonin's glucose and exposure effects as the more relevant safety question, independent of the LDN.
What low-dose naltrexone is understood to do
Standard-dose naltrexone blocks opioid receptors continuously to reduce the reinforcing effects of opioids or alcohol. The low-dose theory, developed mainly through small pilot studies rather than large regulatory trials, proposes that a brief, several-hour receptor blockade at night triggers a rebound increase in the body's own opioid peptides (beta-endorphin, met-enkephalin) once the blockade wears off, and that naltrexone may also dampen microglial activation through toll-like receptor 4 (TLR4), a pathway separate from classical opioid receptor binding.
This mechanism is plausible and has support from small trials in fibromyalgia and other pain and autoimmune conditions, but it has not been confirmed at the scale or with the regulatory rigor of an FDA-approved indication. Prescribers typically dose LDN in the evening on the reasoning that this timing lines up with the body's natural nighttime endorphin activity, though the ideal timing has not been established in a head-to-head trial.
What melatonin is understood to do, and where it overlaps with LDN
Melatonin acts on MT1 and MT2 receptors in the brain's suprachiasmatic nucleus to shift circadian timing and shorten the time it takes to fall asleep. Separately, melatonin has documented antioxidant and immune-modulating properties in laboratory and animal research, with effects on inflammatory signaling pathways such as NF-kB. Because LDN's proposed benefit also runs partly through anti-inflammatory, glial-pathway effects, the two agents are plausibly working on overlapping biology. This overlap is a reasonable basis for extra attentiveness, not a basis for avoiding the combination. No published human trial has measured LDN and melatonin used together, so any claim about an additive clinical benefit or added risk from this specific overlap is inference, not demonstrated fact.
Animal research has also suggested melatonin can influence endogenous beta-endorphin release, which would sit in the same general system LDN is thought to act on. This is a mechanistic curiosity worth naming honestly as unproven in humans rather than treated as a reason for confidence in either direction.
The glucose question, which is the more concrete concern
MT1 and MT2 receptors are also expressed on pancreatic beta cells, and activating them can reduce insulin secretion. Genetic studies have linked variants in the melatonin receptor gene MTNR1B to higher fasting glucose and greater type 2 diabetes risk, and this receptor biology is a more consistently replicated finding than the LDN-melatonin overlap discussed above. For most healthy adults taking melatonin in the 0.5 mg to 3 mg sleep-dose range, the effect on glucose is expected to be small. People with type 2 diabetes, pre-diabetes, or insulin resistance are the group where this deserves a specific conversation with a prescriber before adding melatonin, particularly at doses above 5 mg. This effect belongs to melatonin itself and has nothing to do with LDN; LDN has no established direct effect on glucose metabolism.
Is this a drug-drug interaction in the pharmacokinetic sense?
No. Naltrexone's metabolism does not run through the cytochrome P450 system in any major way, and melatonin's metabolism through CYP1A2 does not intersect with naltrexone's clearance pathway. Interaction-checking databases generally classify this pairing as having insufficient data to assign a severity rating, rather than as a confirmed low-risk or high-risk interaction. That distinction matters: "insufficient data" means the combination has not been formally studied, not that it has been studied and cleared.
One clinically important interaction does exist, but it does not involve LDN at all: drugs that inhibit CYP1A2, such as fluvoxamine and ciprofloxacin, can substantially raise melatonin blood levels. A person on LDN who is also taking a CYP1A2 inhibitor and starts melatonin should treat that combination, not the LDN-melatonin pairing, as the interaction that needs prescriber input.
Timing: does it matter if I take them together?
There is no documented harm from taking LDN and melatonin at the same moment. A cautious, low-burden approach some prescribers suggest is to take LDN first at bedtime and wait roughly an hour before taking melatonin, so that peak drug exposure for each is somewhat staggered. This is a practical convenience recommendation drawn from general pharmacokinetic reasoning about naltrexone's absorption, not a rule established by a trial comparing simultaneous versus staggered dosing.
A commonly used starting approach:
- Take LDN at the prescribed evening time
- Wait about an hour
- Take melatonin, starting at a low dose (0.5 mg to 1 mg) roughly 30 minutes before intended sleep time
People who take LDN in the morning, which some autoimmune protocols use, have no bedtime timing conflict with melatonin at all.
Who should be more careful
- People with diabetes, pre-diabetes, or insulin resistance: check fasting glucose when starting melatonin and report unexpected changes to a prescriber.
- People taking CYP1A2 inhibitors (examples include fluvoxamine and ciprofloxacin): melatonin exposure can rise substantially; start at the lowest available dose and involve a pharmacist or prescriber.
- People newly starting LDN: vivid dreams and sleep disruption are a commonly reported early side effect during the first weeks of LDN titration. Starting melatonin at the same time makes it harder to tell which agent is causing a new sleep change. Waiting until LDN dosing has stabilized, when clinically appropriate, makes cause and effect easier to sort out.
- People with autoimmune conditions on LDN who also have significant fatigue or sleep disruption: melatonin has been studied in some of these populations for reasons unrelated to LDN, but the combined effect with LDN has not been tested and should not be assumed to be simply additive.
- Pregnant individuals: LDN and melatonin should each be discussed with a physician before use in pregnancy; neither is addressed by strong pregnancy-specific safety data in this context.
When to seek urgent care rather than wait and monitor
Contact a prescriber promptly, or seek urgent care, for any of the following after starting or adjusting either agent: signs of a severe allergic reaction (swelling, difficulty breathing, hives), unusual or severe sedation that impairs safe function the next day, new or worsening symptoms of high or low blood sugar in someone with diabetes, or any symptom that feels medically urgent regardless of whether it seems related to a supplement. Routine questions about dose adjustment or timing belong in a scheduled conversation with the prescribing clinician or a pharmacist, not urgent care.
Evidence-status interaction assessment
| Status | Claim | Basis |
|---|---|---|
| Established | No pharmacokinetic interaction between naltrexone and melatonin (separate metabolic pathways: carbonyl reductase vs. CYP1A2) | Consistent with general pharmacology of each compound; not contradicted by any known interaction report |
| Established | Melatonin can raise blood glucose response and reduce insulin secretion via MT1/MT2 receptors on beta cells, more relevant at higher doses or in glucose-intolerant individuals | Supported by receptor biology and genetic association research; independent of LDN |
| Established | CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin) can raise melatonin exposure meaningfully | Consistent with melatonin's known metabolic pathway |
| Plausible but unproven | LDN and melatonin have additive anti-inflammatory or endorphin-related effects when combined | Each agent affects overlapping biological systems separately; no trial has tested the combination |
| Not established | Any specific numeric estimate of combined benefit or risk from taking LDN and melatonin together | No controlled human trial exists on this specific combination |
| Requires verification with a pharmacist or prescriber | Individual timing, dosing, and monitoring plan, especially with diabetes, CYP1A2-inhibiting medications, or other LDN-affecting conditions | Individualized clinical judgment, not something a general article can resolve |
Evidence boundary
What is established: naltrexone and melatonin do not share a metabolic clearance pathway, and no confirmed pharmacokinetic interaction exists between them. Melatonin's effect on insulin secretion at the receptor level is a real and independently documented phenomenon. What is plausible but unproven: that combining LDN and melatonin produces an additive anti-inflammatory or mood/pain benefit through overlapping endorphin and cytokine pathways. What is not established: any specific magnitude of benefit or harm from using the two together, because the combination has not been the subject of a controlled clinical trial. Readers should not treat mechanistic plausibility as equivalent to clinical proof in either direction.
A note on sourcing for this revision: several specific study citations, quoted statements, and precise effect-size figures that appeared in an earlier version of this article could not be verified against their stated sources during this review and have been removed or converted to general, unattributed statements pending confirmation by clinical review. Readers and reviewing clinicians should treat any numeric claim in older material about this topic with caution until it is checked against the primary literature or a current interaction database such as the Natural Medicines Database.
Practical takeaways
LDN and melatonin are not considered a contraindicated combination, and no pharmacokinetic collision has been documented. The most concrete individual-level consideration is melatonin's own effect on glucose regulation in susceptible people, which has nothing to do with LDN. A reasonable starting approach is a low melatonin dose (0.5 mg to 1 mg), taken roughly an hour after an evening LDN dose, with glucose monitoring in the first couple of weeks for anyone with diabetes or pre-diabetes, and disclosure of melatonin use to the LDN-prescribing clinician regardless of dose.
Frequently asked questions
Can I take melatonin while on low-dose naltrexone?
Does melatonin interact with low-dose naltrexone?
What time should I take melatonin if I take LDN at bedtime?
Can melatonin affect blood sugar in LDN users?
Does melatonin reduce the effectiveness of low-dose naltrexone?
Should I tell my LDN prescriber I am taking melatonin?
Are there people who should avoid combining melatonin and LDN without medical guidance?
References
- U.S. Food and Drug Administration, drug label and approval information for naltrexone hydrochloride tablets and injection (standard-dose formulations): fda.gov
- National Institutes of Health, Office of Dietary Supplements, fact sheet on melatonin: general background on formulation, regulation, and typical use
- Natural Medicines Database, interaction summary for naltrexone and melatonin (subscription resource; consult directly for current interaction rating)
This article summarizes general pharmacology and mechanism-level reasoning. It does not provide an individualized dosing or monitoring plan, and specific questions about combining these agents should go to the prescribing clinician or a pharmacist familiar with the individual's full medication list.